Trials / Recruiting
RecruitingNCT06993610
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 225 (estimated)
- Sponsor
- Zura Bio Inc · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tibulizumab Dose A | Anti BAFF/IL-17 antibody. ZB-106 |
| BIOLOGICAL | Tibulizumab Dose B | Anti BAFF/IL-17 antibody. ZB-106 |
| OTHER | Placebo | ZB-106 Placebo |
Timeline
- Start date
- 2025-05-16
- Primary completion
- 2026-11-01
- Completion
- 2027-04-01
- First posted
- 2025-05-29
- Last updated
- 2026-02-12
Locations
56 sites across 6 countries: United States, Canada, Germany, Hungary, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06993610. Inclusion in this directory is not an endorsement.